Stan B Kaye

Summary

Affiliation: Royal Marsden Hospital
Country: UK

Publications

  1. ncbi A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
    S B Kaye
    CRUK Department of Medical Oncology, The Royal Marsden Hospital and The Institute of Cancer Research, Surrey, UK
    Ann Oncol 24:145-52. 2013
  2. ncbi A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission
    Stanley B Kaye
    Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Clin Cancer Res 18:6509-18. 2012
  3. ncbi Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
    S Kaye
    Drug Development Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 106:1728-34. 2012
  4. ncbi Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
    Stan B Kaye
    The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sycamore House, Downs Rd, Sutton, Surrey SM2 5PT, UK
    J Clin Oncol 30:372-9. 2012
  5. ncbi Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial
    S B Kaye
    Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Int J Gynecol Cancer 15:31-5. 2005
  6. ncbi Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
    S B Kaye
    Section of Medicine, Institute of Cancer Research, The Royal Marsden Hospital, Sutton, Surrey, UK
    Ann Oncol 22:49-58. 2011
  7. ncbi Beyond chemotherapy: targeted therapies in ovarian cancer
    Timothy A Yap
    The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Nat Rev Cancer 9:167-81. 2009
  8. ncbi Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
    Peter C Fong
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, UK
    J Clin Oncol 28:2512-9. 2010
  9. ncbi Weekly paclitaxel in the treatment of recurrent ovarian cancer
    Richard D Baird
    Section of Medicine, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK
    Nat Rev Clin Oncol 7:575-82. 2010
  10. ncbi The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer
    Craig P Carden
    Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutic, The Institute of Cancer Research, Sutton, United Kingdom
    Mol Cancer Ther 11:1609-17. 2012

Detail Information

Publications70

  1. ncbi A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
    S B Kaye
    CRUK Department of Medical Oncology, The Royal Marsden Hospital and The Institute of Cancer Research, Surrey, UK
    Ann Oncol 24:145-52. 2013
    ..This randomized phase II study evaluated efficacy and safety of pertuzumab in combination with carboplatin-based chemotherapy in patients with platinum-sensitive, recurrent advanced ovarian cancer...
  2. ncbi A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission
    Stanley B Kaye
    Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Clin Cancer Res 18:6509-18. 2012
    ..This phase II, randomized, double-blind, placebo-controlled trial was designed to provide a preliminary estimate of efficacy in patients with ovarian cancer in second or third complete remission (CR)...
  3. ncbi Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
    S Kaye
    Drug Development Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 106:1728-34. 2012
    ..As a prelude to combination studies aimed at resistance reversal, this dose-escalation/dose-expansion study investigated the selective Src kinase inhibitor saracatinib (AZD0530) in combination with carboplatin and/or paclitaxel...
  4. ncbi Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
    Stan B Kaye
    The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sycamore House, Downs Rd, Sutton, Surrey SM2 5PT, UK
    J Clin Oncol 30:372-9. 2012
    ..We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population...
  5. ncbi Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial
    S B Kaye
    Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Int J Gynecol Cancer 15:31-5. 2005
    ..When the treatment-free interval was between 6 and 12 months, the extent of the benefit was less clear and further trials are certainly warranted...
  6. ncbi Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
    S B Kaye
    Section of Medicine, Institute of Cancer Research, The Royal Marsden Hospital, Sutton, Surrey, UK
    Ann Oncol 22:49-58. 2011
    ..This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy...
  7. ncbi Beyond chemotherapy: targeted therapies in ovarian cancer
    Timothy A Yap
    The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Nat Rev Cancer 9:167-81. 2009
    ..Importantly, such strategies might allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine...
  8. ncbi Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
    Peter C Fong
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, UK
    J Clin Oncol 28:2512-9. 2010
    ..Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers...
  9. ncbi Weekly paclitaxel in the treatment of recurrent ovarian cancer
    Richard D Baird
    Section of Medicine, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK
    Nat Rev Clin Oncol 7:575-82. 2010
    ..Current research topics include the combination of weekly paclitaxel with molecular-targeted agents and the use of molecular profiling to better select patients for treatment...
  10. ncbi The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer
    Craig P Carden
    Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutic, The Institute of Cancer Research, Sutton, United Kingdom
    Mol Cancer Ther 11:1609-17. 2012
    ..There is no clear evidence that this is driven specifically by PIK3CA or AKT mutations or by amplifications or deletion of PTEN...
  11. ncbi Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity
    Christina Messiou
    Cancer Research UK and EPSRC Imaging Centre and Drug Development Unit of Section of Medicine, Institute of Cancer Research and Royal Marsden Hospital, MRI Unit, Downs Road, Sutton, Surrey SM2 5PT, England Department of Radiology, Royal Marsden NHS Foundation Trust, Sutton, Surrey, England
    Radiology 265:426-36. 2012
    ..RSNA, 2012 Clinical trial registration no. NCT00748891 Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12112565/-/DC1...
  12. ncbi Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development
    Daniel S W Tan
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK
    Cancer J 15:406-20. 2009
    ....
  13. ncbi Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Craig P Carden
    Drug Development Unit, Royal Marsden Hospital, Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Drug Discov Today 15:88-97. 2010
    ..In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents...
  14. ncbi Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
    Emma Kipps
    The Institute of Cancer Research Royal Marsden Hospital, Medicine, Downs Road, Sutton SM2 5PT, UK
    Nat Rev Cancer 13:273-82. 2013
    ....
  15. ncbi Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors
    Laura Vidal
    Drug Development Unit, Royal Marsden Hospital, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Invest New Drugs 30:616-28. 2012
    ..This study intended to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RD) of trabectedin combined with carboplatin in patients with advanced solid tumors...
  16. ncbi Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients
    Stavroula Kyriazi
    Cancer Research UK and EPSRC Cancer Imaging Centre, Research Data Management and Statistics Unit, and Department of Gynaecological Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey SM2 5PT, England
    Radiology 261:182-92. 2011
    ..To prospectively evaluate apparent diffusion coefficient (ADC) histograms in the prediction of chemotherapy response in patients with metastatic ovarian or primary peritoneal cancer...
  17. ncbi Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials
    David Olmos
    Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
    Clin Cancer Res 17:5188-96. 2011
    ..We hypothesized that the incorporation of CTC counts might improve patient selection for phase I trials...
  18. ncbi PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers
    Craig P Carden
    The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
    Curr Opin Oncol 22:473-80. 2010
    ..The strategy of identifying biologically distinct subgroups of ovarian cancer by means of clinical characteristics, histology and molecular profiling is an exciting prospect in personalizing and improving therapy for ovarian cancer...
  19. ncbi Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
    Robin L Jones
    Royal Marsden Hospital, London, SW3 6JJ, UK
    Cancer Chemother Pharmacol 68:423-9. 2011
    ..The aim of this study was to evaluate the clinical benefit for sarcoma patients treated within the Phase I Unit of a single referral centre...
  20. ncbi Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers
    Geraldine Perkins
    Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    PLoS ONE 7:e47020. 2012
    ..Overall, circulating nucleic acid biomarker studies have clinically important multi-purpose utility in advanced cancer patients and further studies to pursue their incorporation into the standard of care are warranted...
  21. ncbi The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin
    James Witham
    Section of Medicine, The Institute of Cancer Research, Sutton, United Kingdom
    Clin Cancer Res 13:7191-8. 2007
    ..ABT-737 is a recently described inhibitor of members of this family. We investigated whether this compound could sensitize ovarian cancer cells to chemotherapeutic agents...
  22. ncbi Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
    David Olmos
    The Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
    J Clin Oncol 30:996-1004. 2012
    ..This study aims to define prognostic factors to guide risk-benefit assessments by using a large patient database from multiple phase I trials...
  23. ncbi Combining antiangiogenics to overcome resistance: rationale and clinical experience
    Víctor Moreno García
    Division of Clinical Sciences, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom
    Clin Cancer Res 18:3750-61. 2012
    ..However, overlapping and cumulative toxicities pose a real challenge. This review summarizes the preclinical rationale for this approach and current clinical experience in combining antiangiogenic therapies...
  24. ncbi Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer
    Gerhardt Attard
    The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 69:2912-8. 2009
    ..007) in CRPC patients treated with abiraterone acetate. These data confirm that CTCs are malignant in origin and indicate that hormone-regulated expression of ERG persists in CRPC...
  25. ncbi Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
    Martin D Forster
    Drug Development Unit, Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Nat Rev Clin Oncol 8:302-6. 2011
    ..She had received several lines of chemotherapy for multiple relapses over 9 years and displayed a profound sensitivity to platinum-containing regimens...
  26. ncbi Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies
    Timothy A Yap
    Royal Marsden National Health Service Foundation Trust, The Institute of Cancer Research, Sutton, Surrey, UK
    J Clin Oncol 29:1271-9. 2011
    ..A phase I trial of ARQ 197 was conducted to assess safety, tolerability, and target inhibition, including intratumoral c-MET signaling, apoptosis, and angiogenesis...
  27. ncbi Expression profiling and individualisation of treatment for ovarian cancer
    Roshan Agarwal
    Section of Medicine, Institute for Cancer Research, Royal Marsden Hospital, Sycamore House, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Curr Opin Pharmacol 6:345-9. 2006
    ..The ambition of personalised medicine through microarray-based profiling appears to be realistic, but further studies on large uniform cohorts are needed before this potential is fully realised...
  28. ncbi Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy: correlation of apparent diffusion coefficients with epithelial and stromal densities on histology
    Stavroula Kyriazi
    CR UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Cancer Biomark 7:201-10. 2010
    ..77, P< 0.001). There was no significant correlation between ADC and stromal density. Thus ADC reflects mainly epithelial content in advanced ovarian cancer and is not solely a function of lesion cellularity...
  29. ncbi Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer
    David S P Tan
    Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom
    Eur J Cancer 49:1246-53. 2013
    ..A retrospective study was undertaken to investigate the clinical effects of paclitaxel monotherapy in patients with BMOC...
  30. ncbi Ovarian cancer: can we reverse drug resistance?
    David S P Tan
    Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK
    Adv Exp Med Biol 622:153-67. 2008
  31. ncbi Current treatment and clinical trials in ovarian cancer
    Liz Y Han
    Royal Marsden Hospital, The Gynecology Unit, Department of Medicine, Sycamore House, Downs Road, Sutton, Surrey SM2 5PT, UK
    Expert Opin Investig Drugs 19:521-34. 2010
    ..In this review, we outline the seminal trials that influenced our current management as well as introduce recent trials that have provided intriguing results to aid the understanding of ovarian tumour biology...
  32. ncbi A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma
    J E Ang
    Royal Marsden Hospital, London and Sutton, Surrey, UK
    Ann Oncol 20:1787-93. 2009
    ..Platinum compounds, taxanes and anthracyclines provide the major effective drug classes in the treatment of advanced and recurrent endometrial cancer and carcinosarcoma...
  33. ncbi The integration of docetaxel into first-line chemotherapy for ovarian cancer
    S B Kaye
    Dept of Medical Oncology, Royal Marsden Hospital, London, UK
    Int J Gynecol Cancer 11:31-3. 2001
    ..Significant differences in toxicity were seen, and this analysis together with response data is scheduled for presentation at the May 2001 ASCO meeting...
  34. ncbi Chemotherapy for recurrent ovarian cancer
    S B Kaye
    Cancer Research UK Department of Medical Oncology, Royal Marsden Hospital, Sutton, Surrey, UK
    Lancet 361:2094-5. 2003
  35. ncbi Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
    Richard D Baird
    Section of Medicine, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey, United Kingdom
    Mol Cancer Ther 8:1430-7. 2009
    ..At this dose, pharmacologically relevant concentrations of the drug were safely achieved with pharmacogenomic studies indicating changes in the expression of genes of potential mechanistic relevance...
  36. ncbi Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
    Peter C Fong
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, Sutton, Surrey, United Kingdom
    N Engl J Med 361:123-34. 2009
    ..We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor...
  37. ncbi Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy
    Liz Y Han
    Gynecology Unit, Royal Marsden Hospital, London and Surrey, UK
    Eur J Cancer 46:1359-64. 2010
    ....
  38. ncbi The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
    Udai Banerji
    Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Clin Cancer Res 16:1613-23. 2010
    ..In part B, the aim was to compare the pharmacokinetic profile of the new Hyd-Sulfate capsule with the initial AZD6244 free-base suspension and further characterize the pharmacodynamic profile and efficacy of the new formulation...
  39. ncbi Docetaxel in the management of ovarian cancer
    Sarah P Blagden
    Royal Marsden Hospital Downs Road, Sutton, Surrey SM2 5PT, UK
    Expert Rev Anticancer Ther 5:203-14. 2005
    ..However, docetaxel has not yet received approval for standard use. Here, the clinical development of docetaxel and its present and future place in the management of ovarian cancer is discussed...
  40. ncbi Making the best of PARP inhibitors in ovarian cancer
    Susana Banerjee
    The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
    Nat Rev Clin Oncol 7:508-19. 2010
    ..We suggest that it will be crucial to explore novel therapeutic trial strategies and drug combinations, and incorporate robust biomarkers predictive of response if these drugs are to reach their full potential...
  41. ncbi Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer
    M Linch
    Gynaecology Unit, Royal Marsden Hospital, Surrey, UK
    Gynecol Oncol 109:27-32. 2008
    ..This study assessed the current usage of WP in routine clinical practice in a tertiary cancer center...
  42. ncbi First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies
    Timothy A Yap
    Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, UK
    Clin Cancer Res 19:909-19. 2013
    ..A phase I trial was undertaken to determine safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and antitumor activity of OSI-930 in patients with advanced solid tumors...
  43. ncbi Ovarian cancer: strategies for overcoming resistance to chemotherapy
    Roshan Agarwal
    Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK
    Nat Rev Cancer 3:502-16. 2003
    ..A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved...
  44. ncbi Ovarian cancer: progress and continuing controversies in management
    Charlotte Moss
    Department of Medical Oncology, Royal Marsden Hospital, Downs Road, Surrey Sutton, UK
    Eur J Cancer 38:1701-7. 2002
    ..Real progress can be expected when a better understanding is achieved of the mechanisms underlying clinical drug resistance in ovarian cancer, and a close laboratory-clinical interaction is crucial...
  45. ncbi Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
    D P Dearnaley
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:2107-13. 2005
    ..There are no clearcut advantages to 2 x BOP over 2 x BEP, except for patients who wish to maximise the chance of avoiding significant alopecia...
  46. ncbi Drug resistance reversal--are we getting closer?
    R D Baird
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Eur J Cancer 39:2450-61. 2003
    ....
  47. ncbi A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies
    Chooi P Lee
    Royal Marsden Hospital, Sutton, United Kingdom
    Clin Cancer Res 12:2841-8. 2006
    ..To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in patients with advanced solid malignancies...
  48. ncbi Imaging ovarian cancer and peritoneal metastases--current and emerging techniques
    Stavroula Kyriazi
    Section of Magnetic Resonance, Cancer Research UK and EPSRC Cancer Imaging Center, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Nat Rev Clin Oncol 7:381-93. 2010
    ..The combination of functional information with conventional anatomical visualization holds promise to accurately characterize peritoneal disease, and provides noninvasive biomarkers of therapeutic performance and patient prognosis...
  49. ncbi Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
    Gerhardt Attard
    Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 27:3742-8. 2009
    ..Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis...
  50. ncbi Future directions for the management of ovarian cancer
    S B Kaye
    CRC Department of Medical Oncology, Royal Marsden Hospital, Downs Road, Surrey SM2 5PT, Sutton, UK
    Eur J Cancer 37:S19-23. 2001
    ..g. genetic therapy. A better understanding of the mechanisms underlying clinical drug resistance will be important in the rational development of a number of exciting approaches aimed at overcoming this key obstacle...
  51. ncbi Potential clinical applications of epothilones: a review of phase II studies
    J M G Larkin
    Department of Medicine, The Royal Marsden Hospital, Sutton, Surrey, UK
    Ann Oncol 18:v28-34. 2007
    ..Epothilones are cytotoxic macrolides that share a similar mechanism of action with the taxanes but demonstrate antitumor activity in taxane-resistant settings. Six epothilones are in early clinical trials for cancer treatment...
  52. ncbi Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer
    S Bishara
    Department of Gynaecological Oncology, Royal Marsden Hospital, London, UK
    Eur J Obstet Gynecol Reprod Biol 138:71-5. 2008
    ..Here we have investigated their influence on outcome in primary epithelial ovarian cancer...
  53. ncbi Revisiting the role of antiandrogen strategies in ovarian cancer
    Dionysis Papadatos-Pastos
    Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Oncologist 16:1413-21. 2011
    ..A specific example is the new agent abiraterone. In addition, we propose a panel of molecules that could be assessed as potential biomarkers that may aid patient selection for this approach in the future...
  54. ncbi Recent advances in the treatment of epithelial ovarian cancer
    M Harries
    CRC Department of Medical Oncology, The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Expert Opin Investig Drugs 10:1715-24. 2001
    ..Non-cytotoxic approaches that are showing promise include therapies designed to overcome drug resistance, signal transduction inhibitors, immunotherapy and gene therapy...
  55. ncbi A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
    A T Brunetto
    The Royal Marsden Hospital Drug Development and Breast Units and Institute of Cancer Research, Sutton, UK
    Br J Cancer 103:607-12. 2010
    ..This retrospective series reviews the outcome of 70 MBC patients who have participated in 30 phase I trials at the Royal Marsden Hospital from 2002 to 2009...
  56. ncbi Novel therapeutic agents in ovarian cancer
    R Agarwal
    Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK
    Eur J Surg Oncol 32:875-86. 2006
    ..This article systematically reviews novel therapeutic strategies that have been evaluated in patients with ovarian cancer in the last 5 years...
  57. ncbi Gliomatosis peritonei: MRI appearances and its potential role in follow up
    R A England
    Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK nhs uk
    Br J Radiol 80:e101-4. 2007
    ..We present a case of immature ovarian teratoma complicated by the development of low grade gliomatosis peritonei. The MRI appearances are presented and described, and we discuss the potential role of MRI in the follow up of such cases...
  58. ncbi A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG)
    N S Reed
    Beatson Oncology Centre, Western Infirmary, EORTC Gynaecological Cancer Group, Dumbarton Road, Glasgow G11 6NT, UK
    Eur J Cancer 42:179-85. 2006
    ..With the exception of myelosuppression, toxicity was mild in both arms. Carboplatin remains the gold standard in this older and less fit group of patients...
  59. ncbi Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment
    G Pentheroudakis
    CRC Department of Medical Oncology, Western Infirmary, Glasgow, Scotland, UK
    BJU Int 92:36-42. 2003
    ....
  60. ncbi A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer
    V J O'Neill
    Cancer Research UK Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow GL1 6NT, UK
    Br J Cancer 86:1385-90. 2002
    ..The predefined maximum tolerated dose was exceeded in cohort 3. The cohort 4 dose level (epirubicin 50 mg m(-2), carboplatin AUC 4, docetaxel 75 mg m(-2)), warrants further study...
  61. ncbi Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours
    D A Anthoney
    Department of Medical Oncology, Beatson Oncology Centre, Glasgow, UK
    Br J Cancer 90:601-6. 2004
    ..Bleomycin, vincristine, cisplatin (BOP)/bleomycin, etoposide, cisplatin (BEP) represents a practicable, well-tolerated, dose intense chemotherapy regimen with significant activity in intermediate and poor prognosis MGCT...
  62. ncbi A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer
    P A Vasey
    Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, UK
    Br J Cancer 89:1843-8. 2003
    ..The convenience and improved safety profile of capecitabine compared with intravenous. regimens make it an ideal agent for administration in the outpatient setting...
  63. ncbi Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial
    S V Barrett
    Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
    Ann Oncol 19:898-902. 2008
    ..We sought to test the hypothesis that obesity reduces survival in a large, well-characterised and relatively homogeneous cohort of ovarian cancer patients...
  64. ncbi First-line chemotherapy for ovarian cancer - the controversy continues
    S B Kaye
    Br J Cancer 87:813-4. 2002
  65. ncbi Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer
    P A Vasey
    Beatson Oncology Centre and Stobhill Hospital, Glasgow, United Kingdom
    J Clin Oncol 20:1562-9. 2002
    ....
  66. ncbi Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
    P A Vasey
    Department of Medical Oncology, Cancer Research UK, West of Scotland Clinical Trials Unit, Beatson Oncology Centre, E Block, Western Infirmary, Glasgow, G11 6NT, Scotland, UK
    Br J Cancer 87:1072-8. 2002
    ..These findings establish a recommended dose of docetaxel 75 mg m(-2) in combination with cyclophosphamide 600 mg m(-2) every three weeks for phase II evaluation...
  67. ncbi Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre
    B Pamenter
    The University Department of Urology, Western Infirmary, Gartnavel General, and Stobhill Hospitals, Glasgow, UK
    BJU Int 92:43-6. 2003
    ..8-5% of such patients will subsequently develop a new primary tumour in the contralateral testis...
  68. ncbi Chemotherapy for ovarian cancer: yesterday, today and tomorrow
    S B Kaye
    Br J Cancer 89:S1-2. 2003
  69. ncbi Prognostic factors in ovarian cancer: how close are we to a complete picture?
    R Agarwal
    Ann Oncol 16:4-6. 2005
  70. ncbi Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    J Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 20:4292-302. 2002
    ....